Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. 1997

A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
Institute of Gynecology and Obstetrics, University of Perugia, Italy.

p53 and c-erbB-2 protein expression was immunohistochemically examined in a consecutive series of 49 primary breast cancer patients with a 10-year follow-up. The study was performed on paraffin sections using the monoclonal antibodies DO7 and CBE1; the former recognizes both the wild-type and the mutant p53 forms, the latter recognizes the external domain of the transmembrane c-erbB-2 protein. Positive staining was expressed in 12.2% and 16.3% of cases for p53 and c-erbB-2 proteins, respectively. The results were related to clinicopathological parameters by the chi 2 test. A significant correlation was found between positive c-erbB-2 immunostaining and poor survival (P = 0.04) and between p53 and c-erbB-2 overexpression (P = 0.003); this co-overexpression correlated well with a poor clinical outcome (P = 0.040). From our results, we may speculate that simultaneous expression of p53 and c-erbB-2 oncoproteins could be a critical event in breast tumor progression, and therefore, of prognostic value to identify patients at high risk.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein

Related Publications

A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
March 2004, Indian journal of experimental biology,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
April 1989, Cancer research,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
September 1998, Breast cancer research and treatment,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
January 1996, Pathology international,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
March 1991, British journal of cancer,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
September 1998, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
January 2000, Journal of surgical oncology,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
July 1987, Lancet (London, England),
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
April 1994, Cancer,
A Barbati, and E V Cosmi, and A Sidoni, and P Collini, and M G Porpora, and I Ferri, and M Lüthy, and V Lauro, and E Bucciarelli
September 1993, British journal of cancer,
Copied contents to your clipboard!